Stifel Financial
PHAS

Stifel Financial’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Stifel Financial’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,721
Closed -$2K – 3432
2022
Q3 		$2K Sell
13,721
-425,544
-97% -$434K ﹤0.01% 3269
2022
Q2 		$264K Buy
439,265
+147,267
+50% +$141K ﹤0.01% 2820
2022
Q1 		$385K Buy
291,998
+5,739
+2% +$9.3K ﹤0.01% 2726
2021
Q4 		$747K Sell
286,259
-6,581
-2% -$19.9K ﹤0.01% 2332
2021
Q3 		$911K Buy
292,840
+30,147
+11% +$101K ﹤0.01% 2163
2021
Q2 		$977K Buy
262,693
+16,806
+7% +$55.9K ﹤0.01% 2122
2021
Q1 		$851K Buy
245,887
+35,762
+17% +$145K ﹤0.01% 2099
2020
Q4 		$706K Buy
210,125
+22,288
+12% +$79.8K ﹤0.01% 2097
2020
Q3 		$659K Buy
187,837
+10,651
+6% +$42.9K ﹤0.01% 1915
2020
Q2 		$815K Sell
177,186
-682
-0.4% -$3.02K ﹤0.01% 1706
2020
Q1 		$566K Buy
177,868
+14,825
+9% +$67.9K ﹤0.01% 1782
2019
Q4 		$981K Sell
163,043
-40,415
-20% -$166K ﹤0.01% 1846
2019
Q3 		$844K Buy
203,458
+130,497
+179% +$1.04M ﹤0.01% 1859
2019
Q2 		$951K Buy
+72,961
New +$894K ﹤0.01% 1838

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Stifel Financial's PHAS Position: Q4 2022 in Review

Stifel Financial sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 13,721 shares — an estimated $2K sold.

Stifel Financial first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $981K in Q4 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Stifel Financial reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Stifel Financial sold 13,721 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $2K.
  • Stifel Financial first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
  • Stifel Financial's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $981K in Q4 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Stifel Financial's 13F filing for Q4 2022, filed 13 Feb 2023.